TRIM56 and breast carcinoma: Through the analysis of publicly available clinical breast cancer database (http://kmplot.com/analysis/), we observed that TRIM56 expression level correlates with poor endocrine treatment outcome (Fig. 1A–C), but correlates with favorable survival time in triple-negative breast cancer patients (Supplementary Fig. 1A).